Shares of biopharmaceutical company CytRx ( CYTR) gained 5.3% after the company said its RXi Pharmaceuticals subsidiary is licensing technology to the University of Massachusetts Medical School. Shares were up 11 cents to $2.19 in premarket trading Thursday. The exclusive license involves RNA interference, the company says. The university will also have the right to sublicense the so-called nanotransporter technology, which was shown to deliver RNA interference to different types of tissues in animal trials. Financial terms were not disclosed.